ITM2B

Across TCGA pan-cancer cohorts, ITM2B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ITM2B data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ITM2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ITM2B expression acts as an unfavorable survival marker.

ESCA and SKCM are the cancer types where ITM2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
SKCM	OS	Median	II,III,IV	0.175	0.739	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ITM2B–ESCA (OS)

Open the ESCA breakdown →